Despite the lack of effectiveness of clinical evidence, we speculate that longer term and/or a combined therapy with other anti-cancer compounds may improve anti-tumoral effects of synthetic PPARγ agonists in breast cancer patients. The gene discussed is PPARG; the disease is breast carcinoma.